Based on the Actinium Pharmaceuticals Inc stock forecast from 4 analysts, the average analyst target price for Actinium Pharmaceuticals Inc is USD 23.25 over the next 12 months. Actinium Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Actinium Pharmaceuticals Inc is Very Bearish, which is based on 0 positive signals and 5 negative signals. At the last closing, Actinium Pharmaceuticals Inc’s stock price was USD 7.06. Actinium Pharmaceuticals Inc’s stock price has changed by -2.62% over the past week, -23.26% over the past month and -24.81% over the last year.
No recent analyst target price found for Actinium Pharmaceuticals Inc
No recent average analyst rating found for Actinium Pharmaceuticals Inc
Company Overview Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, Iomab-B (I-131 apamistamab) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iomab-ACT for GeneTx and cell therapy conditioning, Actimab-A (CD33) and CLAG-M, Actimab-A (CD33) and Venetoclax, and Actimab-A (CD33) and Venetoclax with HMA. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 -SIRPa immunotherapy targeted radiotherapy; AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors; and Immedica pharma for licensed the rights to commercialize Iomab-B. The company is based in New York, New York. Address: 100 Park Avenue, New York, NY, United States, 10017 Read Less
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, Iomab-B (I-131 apamistamab) that is in a pivotal Phase III...Read More
Frequently Asked Questions About Actinium Pharmaceuticals Inc (ATNM) Stock
Based on ratings from 4 analysts Actinium Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on ATNM's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for ATNM is USD 23.25 over the next 12 months. The maximum analyst target price is USD 26 while the minimum anlayst target price is USD 20.
Unfortunately we do not have enough data on ATNM's stock to indicate if its overvalued.
The last closing price of ATNM's stock was USD 7.06.
The most recent market capitalization for ATNM is USD 0.20B.
Based on targets from 4 analysts, the average taret price for ATNM is projected at USD 23.25 over the next 12 months.
This means that ATNM's stock price may go up by +229.32% over the next 12 months.
We can't find any ETFs which contains Actinium Pharmaceuticals Inc's stock.
As per our most recent records Actinium Pharmaceuticals Inc has 49 Employees.
Actinium Pharmaceuticals Inc's registered address is 275 Madison Avenue, New York, NY, United States, 10016.
You can get more information about it from Actinium Pharmaceuticals Inc's website at https://www.actiniumpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ATNM !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
